Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) in which fat accumulates in the liver causing inflammation, scarring, and other damage. Weight reduction, exercise, cholesterol reduction, and diabetes care can reduce the impact of NASH, but no medications have been approved to treat or reverse the disease ¹. Left untreated, NASH can lead to cirrhosis, liver failure, and liver cancer, as well as an increased incidence of and fatality from cardiovascular disease ^{2 3}.

Around 3-12% of adults in the United States have NASH currently ⁴. Globally, the NASH drug treatment market is expected to exceed $61 billion (USD) by 2028, with a CAGR of 39.4% over the preceding decade ⁵.

1 NIDDK website
2 Azzam H, Malnick S. Non-alcoholic fatty liver disease—the heart of the matter. World Journal of Hepatology. 2015;7(10)1369–1376.
3 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2023.
4 Spengler EK, Loomba R. Recommendations for diagnosis, referral for liver biopsy, and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mayo Clinic Proceedings. 2015;90(9):1233–1246.
5 ResearchAndMarkets